NCT04814368 - A Safety and Efficacy Study of Anti-inflammatory (Canakinumab) and Cartilage Stimulating (LNA043) Drugs Injected Into the Knee Joint of Participants With Knee Osteoarthritis (OA) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 27, 2021

Primary Completion Date

June 24, 2024

Study Completion Date

June 24, 2024

Conditions

Knee Osteoarthritis

Interventions

BIOLOGICAL

canakinumab

Canakinumab 600 mg single intra-articular injection (into the knee) on Day 1

BIOLOGICAL

LNA043

LNA043 40 mg intra-articular injection (into the knee) every 4 weeks, on Days 15, 43 and 71

OTHER

Placebo to canakinumab

Placebo to canakinumab single intra-articular injection (into the knee) on Day 1

Trial Locations (11)

Novartis Investigative Site, Riga

Novartis Investigative Site, Budapest

Novartis Investigative Site, Kecskemét

Novartis Investigative Site, Prague

Lucas Research, Morehead City

Precision Clinical Research LLC, Sunrise

Clinical Res Of W Florida, Clearwater

Novartis Investigative Site, Tartu

LV Research, Las Vegas

Horizon Clinical Research, La Mesa

Novartis Investigative Site, Warsaw